AETERNA ZENTARIS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.57 CAD | +0.17% |
|
+4.33% | +12.55% |
| May. 17 | Aeterna Zentaris Finalizes Some Details for Ceapro Merger | MT |
| May. 17 | Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro | MT |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to Aeterna Zentaris rep...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.
Calendar
2024-07-01
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| +12.55% | 10.32M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- AEZS Stock
- News Aeterna Zentaris Inc.
- Transcript : Aeterna Zentaris Inc., Q3 2018 Earnings Call, Nov 07, 2018
